A multicenter retrospective study has provided the first real-world evidence supporting the use of firsekibart, an anti-interleukin-1 beta monoclonal antibody, in patients with frequent acute gout flares. The analysis included 50 patients treated with either firsekibart 200 mg (n=25) or compound betamethasone 7 mg (n=25). Both treatments achieved comparable pain reduction at 48 hours, indicating similar efficacy for acute symptom control. However, firsekibart demonstrated a significant advantage in preventing recurrent flares.
No patients receiving firsekibart experienced a flare within 12 weeks, compared with 44% of those treated with compound betamethasone. Further analysis confirmed a 97% reduction in flare risk at 12 weeks and an 88% reduction at 24 weeks with firsekibart. In addition, median C-reactive protein levels declined significantly from 14.20 mg/L to 3.85 mg/L, indicating…
